Therefore, a small molecule is identified through virtual screening that specifically disrupts the Smad1‐p300 interaction, offering a promising strategy for inhibiting GBM and increasing chemosensitivity by inhibiting Smad1 acetylation and restoring p53 acetylation. This evidence concerns the gene SMAD1 and glioblastoma.